Sector News

J&J Vision sets sights on childhood myopia with new FDA contact lens clearance

May 16, 2021
Life sciences

Described as a quietly growing epidemic with lifelong complications—and getting considerably less coverage than other international pandemics—nearsightedness and preventable blindness has become a growing concern for healthcare organizations around the world.

Now, Johnson & Johnson Vision has won FDA approval for the first contact lenses designed to reshape the curve of the cornea and help treat the progression of myopia in children.

Designed to be worn overnight, the Acuvue Abiliti orthokeratology lenses are specifically fitted to match each eye based on its unique shape, including for people with and without astigmatism.

The agency’s green light comes quickly on the heels of a global manufacturing partnership with the Japanese contact lens producer Menicon, first announced in early April with a special focus on tackling childhood myopia.

It also follows J&J’s curtain-raising late last month for its new Acuvue Abiliti brand, which will encompass not just lenses but also future products and services geared toward parents and eye care professionals.

This includes software for gauging the topography of the cornea, measuring its shape and merging those features with corrective prescriptions to offer clearer vision. The Abiliti Overnight contacts, meanwhile, are slated to become available by the end of this year, according to the company.

Myopia poses a bigger threat than being unable to read signs at a distance. Children under 12 with the progressive condition are at a higher risk of developing eye diseases, detached retinas and blindness later in life.

At the same time, the prevalence of nearsightedness is increasing: J&J estimates half of the world’s population will be affected by the year 2050, with at least one billion severe cases.

The FDA previously approved CooperVision’s contact lens to help slow the progression of childhood nearsightedness in late 2019.

The company’s soft MiSight lens is made to be discarded at the end of each day, and it works similarly to a typical contact, with the addition of concentric rings around the periphery that split off light and focus it on a point directly in front of the retina, to help reduce the stimulus believed to drive the progression of nearsightedness.

Elsewhere, SightGlass Vision secured a CE mark last summer for its eyeglasses that dampen the amount of visual contrast on the edges of a child’s field of view, allowing the eye to more comfortably focus on objects directly ahead.

by Conor Hale

Source: fiercebiotech.com

comments closed

Related News

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

How can we help you?

We're easy to reach